SAVA241129P32000
- 8.50
- 0.000.00%
Cassava Sciences Newsroom
Cassava Sciences Halts Alzheimer's Drug Trials After Phase 3 Results
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
Trending Stocks Today | Quantum Surges 152.57%
Dow Surges Over 300 Points; Bath & Body Works Posts Upbeat Earnings
JonesTrading Maintains Cassava Sciences(SAVA.US) With Hold Rating
JonesTrading Keeps Their Hold Rating on Cassava Sciences (SAVA)
Sector Update: Health Care Stocks Edge Higher Premarket Monday
Sector Update: Health Care
Cassava Sciences' Alzheimer's Treatment Didn't Meet Endpoints in Study; Shares Dive -- Update
Express News | Cassava Sciences Shares Resume Trading Premarket, Last Down About 85% at $3.94 After Co's Alzheimer's Drug Failed in a Late-Stage Study
Cassava Sciences Shares Are Trading Lower After the Company Announced Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo in Patients With Mild-to-moderate Alzheimer's Disease in the ReThink-ALZ Phase 3 Study.
Express News | Cassava Sciences Shares Are Trading Lower After the Company Announced Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo in Patients With Mild-to-moderate Alzheimer's Disease in the ReThink-ALZ Phase 3 Study
Cassava Sciences to Resume Trading at 8 A.m.
Express News | Cassava Sciences Inc: Also Be Discontinuing Open Label Extension Study
Express News | Cassava Sciences Inc: Simufilam Continued to Demonstrate an Overall Favorable Safety Profile
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
Express News | Cassava Sciences Shares Halted for News Pending Premarket
Express News | Trading Halt: Halted at 7:25:00 A.m. ET - Trading Halt: Halt News Pending